The combination of the nanoparticle albumin-bound paclitaxel + carboplatin + bevacizumab as first-line treatment for advanced non-squamous non-small cell lung cancer is revealed to be favorable and well tolerated in Japanese patients. Here, ALB is linked to non-small cell squamous lung carcinoma.